MX2022015740A - Dosificacion de anticuerpos neutralizantes de poliomavirus. - Google Patents

Dosificacion de anticuerpos neutralizantes de poliomavirus.

Info

Publication number
MX2022015740A
MX2022015740A MX2022015740A MX2022015740A MX2022015740A MX 2022015740 A MX2022015740 A MX 2022015740A MX 2022015740 A MX2022015740 A MX 2022015740A MX 2022015740 A MX2022015740 A MX 2022015740A MX 2022015740 A MX2022015740 A MX 2022015740A
Authority
MX
Mexico
Prior art keywords
neutralizing antibodies
dosing
polyomavirus
polyomavirus neutralizing
pharmaceutical compositions
Prior art date
Application number
MX2022015740A
Other languages
English (en)
Spanish (es)
Inventor
Mark Knapp
Elisabetta Traggiai
Johanna R Abend
Steven J Kovacs
Amy K Patick
Original Assignee
Vera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vera Therapeutics Inc filed Critical Vera Therapeutics Inc
Publication of MX2022015740A publication Critical patent/MX2022015740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
MX2022015740A 2020-06-12 2021-06-11 Dosificacion de anticuerpos neutralizantes de poliomavirus. MX2022015740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038433P 2020-06-12 2020-06-12
PCT/US2021/036923 WO2021252835A1 (en) 2020-06-12 2021-06-11 Dosing of polyomavirus neutralizing antibodies

Publications (1)

Publication Number Publication Date
MX2022015740A true MX2022015740A (es) 2023-03-14

Family

ID=78846596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015740A MX2022015740A (es) 2020-06-12 2021-06-11 Dosificacion de anticuerpos neutralizantes de poliomavirus.

Country Status (12)

Country Link
US (1) US20230220051A1 (enExample)
EP (1) EP4165078A4 (enExample)
JP (1) JP2023550672A (enExample)
KR (1) KR20230029781A (enExample)
CN (1) CN116096746A (enExample)
AU (1) AU2021288699A1 (enExample)
BR (1) BR112022025020A2 (enExample)
CA (1) CA3186736A1 (enExample)
IL (1) IL298956A (enExample)
MX (1) MX2022015740A (enExample)
TW (1) TW202207986A (enExample)
WO (1) WO2021252835A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
CN116322775A (zh) 2020-06-02 2023-06-23 阿雷斯贸易股份有限公司 IgA肾病治疗的相关方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517545A1 (en) * 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
JP6904905B2 (ja) * 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 抗α4β7インテグリン抗体による治療の結果の予測
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
IL298956A (en) 2023-02-01
KR20230029781A (ko) 2023-03-03
CN116096746A (zh) 2023-05-09
CA3186736A1 (en) 2021-12-16
EP4165078A4 (en) 2024-07-17
US20230220051A1 (en) 2023-07-13
WO2021252835A1 (en) 2021-12-16
JP2023550672A (ja) 2023-12-05
BR112022025020A2 (pt) 2023-02-14
AU2021288699A1 (en) 2023-02-09
TW202207986A (zh) 2022-03-01
EP4165078A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
PH12020550967A1 (en) Anti-pd-1 antibodies and methods of treatment
PH12021551409A1 (en) Kif18a inhibitors
MX2021007104A (es) Inhibidores de kif18a.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
MX2022002682A (es) Anticuerpos anti-cd73.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
MX2021001924A (es) Conjugados polimericos de anticuerpo-farmaco dirigidos a napi2b y metodos de uso de los mismos.
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
JOP20190262B1 (ar) مثبطات بيرازول magl
BR112022025020A2 (pt) Dosagem de anticorpos neutralizantes de poliomavírus
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
PH12020551146A1 (en) Methods for treating farber disease
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций
MX2023001157A (es) Formulaciones de anticuerpo anti-integrina beta7 y dispositivos.